CTCSX | NRGSX | CTCSX / NRGSX | |
Total Expense Ratio | 2.05 | 0.74 | 277% |
Annual Report Gross Expense Ratio | 2.10 | 0.74 | 284% |
Fund Existence | 4 years | 13 years | - |
Gain YTD | 20.913 | -3.902 | -536% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 533M | 8.71B | 6% |
Annual Yield % from dividends | 1.53 | 0.06 | 2,352% |
Returns for 1 year | 26.71 | -10.12 | -264% |
Returns for 3 years | 76.04 | 5.90 | 1,288% |
Returns for 5 years | N/A | -2.32 | - |
Returns for 10 years | N/A | 10.24 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
JFNAX | 73.75 | 0.46 | +0.63% |
Janus Henderson Global Life Sciences A | |||
GGCCX | 102.84 | 0.38 | +0.37% |
Gabelli Growth C | |||
GMCUX | 16.77 | 0.04 | +0.24% |
Goldman Sachs Small/Mid Cap Equity R6 | |||
RLEFX | 38.98 | 0.04 | +0.10% |
American Funds American Balanced R5E | |||
MSECX | 11.32 | 0.01 | +0.09% |
Morgan Stanley Inst International Eq C |